PeptIQ/ReportGet the report
First editionAugust 202626 pages50+ cited sources

Independent peptide market intelligence

The State of Peptides

Everyone has an opinion about peptides. Almost nobody has the receipts. This report follows the regulation, money, demand, supply integrity, and evidence—with the weak data labeled in place.

Closed 29 July 2026

The moment in numbers

A category mid-reversal.

These figures are reported by the cited sources and have not been independently audited by PeptIQ. Conflicts are shown, not polished away.

6 of 7peptides recommended by the FDA advisory panel
0 of 7recommended by FDA’s own scientific reviewers
6,441consumer-marketed samples independently tested
41.6–71.1%failed basic quality criteria across two models
15%carried measurable bacterial endotoxin
~8Mworldwide monthly searches for “peptides”
30participants across published BPC-157 pilot studies
55%of active PeptIQ logging was retatrutide alone

Inside the report

Four forces.
One record.

A category-wide view for people making personal, clinical, commercial, editorial, or investment decisions—without pretending those decisions are the same.

01

Regulation

The reversal was real. Legal clarity was not.

A two-day advisory vote recommended six compounds for the 503A bulks list. The report separates three events the market keeps collapsing into one: removal from Category 2, an advisory recommendation, and final rulemaking.

8–6–1

The vote on BPC-157, KPV, and TB-500

02

Money

Follow manufacturing capacity, not the loudest feed.

Market estimates vary by more than 3×, but the underlying capital is less ambiguous: Samsung Biologics is acquiring PolyPeptide for $1.81B while Bachem and CordenPharma expand synthesis capacity.

$1.81B

Samsung Biologics / PolyPeptide transaction

03

Demand

Demand went vertical before policy moved.

Worldwide monthly Google searches for “peptides” rose from roughly 1.3 million in 2024 to around 8 million in 2026. The report maps the microphones, workarounds, and trust shift behind the curve.

6.2×

Two-year growth across measured anchor points

04

Evidence

Thirty people and ten thousand people are not one category.

BPC-157’s published human evidence totals three pilot studies and thirty participants. One ongoing retatrutide cardiovascular outcomes trial targets 10,000. A logarithmic view makes the evidence gap legible.

333×

Difference between 30 and 10,000 participants

The buried story

What is actually in the vial?

Independent analysis of 6,441 consumer-marketed samples found between 41.6% and 71.1% failed basic quality criteria. Fifteen percent carried measurable bacterial endotoxin.

The cited 2026 analysis is a preprint and has not completed peer review. The report labels that limitation alongside the finding.

Share failing criterian = 6,441
41.6%71.1%
7.5%

TB-500 sample pass rate

47.0%

Retatrutide sample pass rate

Why PeptIQ published it

The category has opinions. It needs a record.

Regulators voted without a behavioral record. Clinics assign protocols without one. People run twelve-week cycles from memory. PeptIQ exists to document what happens over time.

74% of long-term users change their active stack month to month.
83% of logged injections are single-compound, despite stack culture online.
93% of TB-500 loggers also track BPC-157—the Wolverine pairing is visible.
PeptIQ takes no vendor, clinic, or sponsor money and runs no affiliate links.
See what PeptIQ tracks

Get the report

Read the receipts.

26 pages. 50+ cited sources. Clear distinctions between primary evidence, institutional analysis, directional estimates, and PeptIQ's own anonymized first-party data.

Informational onlyNot medical adviceNo vendor funding

Access the August 2026 edition.

The report is educational and informational. It does not recommend using, buying, prescribing, starting, stopping, or changing any compound.

Report access does not require marketing consent. Your details are handled under our privacy policy.